Press releases
2017-11-02 – Press release
Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund
- Corporate venture fund invests EUR 4 million (USD 5 million) into Topas
- Financing to accelerate clinical trials in autoimmune diseases
- Detlev Mennerich, Ph.D., Investment Manager of BIVF, to join Topas’ Board ofDirectors
read more …
2017-10-26 – Press release
Topas Therapeutics Appoints Rupert Sandbrink, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer
- Highly accomplished pharmaceutical executive with many years of clinical development, medical affairs, and regulatory experience at Bayer and Schering
- To lead Topas’ clinical development and regulatory affairs
read more …
2017-08-22 – Press release
Topas Therapeutics signs multi-year research and option agreement with Lilly focused on immune tolerance
read more …
2017-04-04 – Press release
Paul Sekhri joins Topas Therapeutics as Chairman of the Board
read more …
2016-03-22 – Press release
Evotec spins off auto-immune disease company as ‘Topas Therapeutics GmbH’
- Topas Therapeutics GmbH is based on a proprietary nanoparticle platform which supports antigen-specific tolerance induction for multiple indications
- Strong consortium consisting of Epidarex Capital, EMBL Ventures, Gimv and Evotec AG supports strategic Series A financing round of EUR 14 m
- Initiation of first clinical trials expected in 2017
read more …